Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments

Goldberg, Ilana; Lichtbroun, Benjamin; Singer, Eric A.; Ghodoussipour, Saum

doi:10.33696/pharmacol.4.030

Arch Pharmacol Ther 2022

DOI: 10.33696/pharmacol.4.030

|View full text |Cite

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments

Ilana Goldberg

Benjamin Lichtbroun

Eric A. Singer

et al.

Abstract: We performed a narrative review using PubMed, Google Scholar, Clinical Key, and Wiley Online Library of articles between the years of 1980 and 2021. Search terms included combinations of terms such as "non-muscle invasive bladder cancer, " "guidelines, " "pharmacotherapy, " "salvage therapy, " and "immunotherapies. " Only original articles published in English were included. Editorials and media articles were not included.For clinical trial information, we searched www.clinicaltrials. gov. This was accessed in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

Moussa,

Abou Chakra,

Shore

et al. 2024

Arch Ital Urol Androl

View full text Add to dashboard Cite

Purpose: To understand the treatment plans suggested for BCG-unresponsive non-muscle invasive disease (NMIBC) patients in the Arab countries and therapeutic decisions applied for BCG-naive patients during BCG shortage time. Methods: A 10-minute online survey was distributed through the Arab Association of Urology (AAU) office to urologists in the Arab countries who treat patients with NMIBC. Results: One hundred six urologists responded to the survey. The majority of urologists had treated, in the past 6 months, > 10 patients with NMIBC who were considered BCG-unresponsive (55% of respondents). Radical cystectomy (RC) was the most popular treatment option (recommended by 50%) for these patients. This was followed by intravesical chemotherapy (30%), repeat BCG therapy (12%), resection with ongoing surveillance (8%). Clinical trials and intravenous checkpoint inhibitors were never selected. The most preferred intravesical chemotherapy was by ranking: 60% gemcitabine, 19% mitomycin C, 8% docetaxel, 8% gemcitabine/docetaxel, 4% sequential gemcitabine/mitomycin C, and 1% valrubicin. The use of intravesical chemotherapy appears limited by Arab urologists due to concerns regarding clinical efficacy (fear of progression) and the lack of clear recommendations by urology societies. Given the BCG shortage, which may vary per Arab country, Arab urologists have adjusted by prioritizing BCG for T1 and carcinoma in situ (CIS) patients over Ta, adapting intravesical chemotherapy, and reducing the dose/strength of BCG administered. Most physicians report an eagerness to utilize novel therapies to address the BCG deficit, especially to try intravesical chemotherapy. Conclusions: Even though Arab urologists are in the majority of cases selecting RC for BCG-unresponsive cases, one-third of them are most recently initiating intravesical chemotherapy as an alternative option. To further assist Arab urologists in the appropriate selection of BCG unresponsive high risk NMIBC patient treatments, enhanced education and pathway protocols are needed.

show abstract

Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

Moussa,

Abou Chakra,

Shore

et al. 2024

Arch Ital Urol Androl

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments

Cited by 1 publication

References 56 publications

Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

Contact Info

Product

Resources

About